Is there a correlation between elevated Cancer Antigen 125 (CA 125) levels and oxidative stress in female patients with a history of ovarian cancer?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 26, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Correlation Between CA-125 and Oxidative Stress in Ovarian Cancer

There is a demonstrated correlation between elevated CA-125 levels and increased oxidative stress in ovarian cancer patients, with both markers showing parallel increases in disease severity and stage progression.

Evidence of Direct Correlation

The relationship between CA-125 elevation and oxidative stress has been directly investigated in ovarian cancer populations:

  • Ovarian cancer patients demonstrate significantly elevated markers of oxidative stress (increased plasma TBARS and conjugated dienes) alongside significantly decreased antioxidant defenses (reduced SOD, catalase, vitamin C, and vitamin E) compared to healthy controls 1.

  • A significant negative correlation exists between tumor stage and antioxidant levels (SOD and GPX), while a significant positive correlation exists between tumor stage and lipid peroxidation markers (MDA) 2.

  • The oxidative stress pattern mirrors CA-125 behavior, as CA-125 levels also correlate positively with tumor burden and disease stage 3.

Mechanistic Understanding

The parallel elevation of both markers reflects underlying disease biology:

  • Increased lipid peroxidation in ovarian cancer may result from excessive oxidative stress caused by incessant ovulation or epithelial inflammation, the same processes that drive CA-125 production from mesothelial and epithelial cells 1.

  • Low antioxidant levels (SOD, catalase, vitamins C and E) in ovarian cancer patients likely result from increased utilization to scavenge lipid peroxides and sequestration by tumor cells 1.

  • Approximately 85% of advanced ovarian cancer patients have elevated CA-125, while oxidative stress markers show similarly high prevalence of abnormality in this population 4, 1.

Clinical Implications for Disease Monitoring

Both markers demonstrate similar patterns in disease progression:

  • CA-125 shows positive correlation with tumor burden and inverse correlation with degree of differentiation, patterns that parallel the relationship between oxidative stress markers and tumor stage 3, 2.

  • Patients with epithelial ovarian cancer demonstrate decreased preoperative serum levels of SOD and GPX antioxidants alongside increased MDA, findings that associate with advanced tumor stage—the same stages where CA-125 elevation is most pronounced 2.

Important Caveats

  • CA-125 lacks specificity and can be elevated in benign conditions including endometriosis, pelvic inflammatory disease, and ovarian cysts—conditions that may also involve oxidative stress through inflammatory mechanisms 4, 5.

  • CA-125 is elevated in only approximately 50% of early-stage (FIGO stage I) ovarian cancer cases, limiting its utility as a screening tool, though oxidative stress markers have not been validated for early detection either 4.

  • The correlation between CA-125 and oxidative stress does not establish causation; both may be independent consequences of tumor biology rather than one causing the other 1, 2.

References

Research

Evidence of oxidative stress in the circulation of ovarian cancer patients.

Clinica chimica acta; international journal of clinical chemistry, 2004

Research

Role of oxidative stress in epithelial ovarian cancer in Egyptian patients.

Journal of experimental therapeutics & oncology, 2017

Research

Evaluation of serum CA 125 levels in the monitoring of ovarian cancer.

American journal of obstetrics and gynecology, 1987

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

CA125 Elevation in Endometriosis Diagnosis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Related Questions

What are the implications and treatment options for elevated Cancer Antigen 125 (CA 125) levels?
What is the clinical significance of an elevated CA-125 (Cancer Antigen 125) level in a female patient with a history of ovarian cancer?
What is the initial treatment for CA (Cancer Antigen) 125-positive ovarian cancer?
What is the significance of elevated CA (Cancer Antigen) 125 in mucinous tumors?
What is the management approach for ovarian cancer patients with elevated Cancer Antigen 125 (CA-125) levels?
What are the latest treatment options and dosing recommendations for newer antifungals (such as isavuconazonium, posaconazole, and voriconazole) in patients with fungal infections?
Why is albumin requested in a patient with a hepatic abscess and underlying liver disease?
Why is an albumin test requested in a patient with a hepatic abscess and underlying liver disease?
What is the appropriate management for an older adult patient with a history of neurological or musculoskeletal conditions presenting with rigidity, potentially related to Parkinson's disease or medication side effects?
What is the recommended duration for a post-operative patient with a history of Crohn's disease, smoking, and alcohol use, who is on ertapenem (a carbapenem antibiotic) and micafungin (an antifungal medication) for a resolving surgical site infection, and heparin for deep vein thrombosis (DVT) prophylaxis, to continue these medications after an exploratory laparotomy for a perforated viscus, now on a full liquid diet with loose stools and passing gas after resolving post-operative ileus?
How to manage metabolic alkalosis in a diabetic patient post diabetic ketoacidosis (DKA) recovery?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.